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Introduction
The discovery of the association between the Wnt signaling pathway and sclerostin with 
bone mass has propelled our understanding of skeletal homeostasis over the last decades. 
Sclerostin is a regulatory secreted glycoprotein that plays a prominent role in skeletal 
homeostasis (1). The major site of sclerostin production is the mature osteocytes in bone; 
however, sclerostin is also found in the circulation. Sclerostin is a potent antagonist of Wnt/β 
catenin signaling. It binds to the Wnt co-receptors LRP4/5/6 and antagonizes downstream 
signaling (2). By inhibiting canonical Wnt signaling, sclerostin decreases bone formation 
and osteoblast differentiation and stimulates bone resorption (1;2). Pharmacological 
inhibition of sclerostin with neutralizing antibodies activates Wnt signaling, robustly 
increases bone formation, and reduces bone resorption in both animal models and humans 
(3;4). Thus, sclerostin has quickly become a valuable therapeutic target for the treatment of 
osteoporosis and other skeletal diseases.
In spite of the rapid advances made over the last years, there are several unresolved enigmas 
regarding sclerostin action. We know that osteoblasts are the main target cells of sclerostin 
and that the major actions of the protein are localized in the skeleton. However, the cellular 
and molecular mechanisms by which monoclonal antibodies to sclerostin increase bone 
mass are not completely understood; and accumulating evidence supports the notion that 
sclerostin modulates the activity of other cells in bone besides osteoblasts. In addition, it is 
not clear why the anabolic effect of pharmacological inhibition of sclerostin wanes with 
time. Further, although the current knowledge suggests that the effects of sclerostin are 
circumscribed to the local bone/bone marrow microenvironment, circulating levels of 
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sclerostin not always reflect the actions observed in bone and the protein might also impact 
cells in non-skeletal tissues.
The current issue of JBMR introduces two articles in which Kim, Wein and colleagues 
examined the effects of pharmacological inhibition of sclerostin on the activity of bone 
lining cells (5) and Fulzele, Divieti Pajevic, and colleagues investigated the effects of 
sclerostin on peripheral white adipocyte tissue (WAT) depots (6). These articles describe two 
previously unknown functions of sclerostin and extend our understanding of the skeletal and 
non-skeletal functions of this regulatory protein.
Sclerostin regulates the pool of quiescent bone lining cells
Bone lining cells cover quiescent bone surfaces and are characterized by their flat 
morphology believed to be indicative of their low matrix biosynthetic activity (7;8). The 
function of bone lining cells remains unclear, but they may represent a source of osteogenic 
precursors. Kim et al show that pharmacological inhibition of sclerostin with neutralizing 
antibodies (Scl-Ab) stimulates the conversion of bone lining cells into active osteoblasts (5). 
The authors used in vivo tamoxifen-inducible cell lineage tracing to genetically label bone 
lining cells and quantified the effects of the Scl-Ab on their thickness as a surrogate of 
cellular activity. They found that Scl-ab administration increased the thickness of lining cells 
covering periosteal and endosteal surfaces of murine cortical bone, while it did not affect 
proliferation or apoptosis of lining cells. This observation is consistent with the conversion 
of lining cells into osteoblasts and lead the authors to conclude that sclerostin regulates the 
pool of quiescent bone lining cells on cortical bone surfaces.
The suggestion that Scl-Ab stimulates conversion of bone lining cells into matrix-producing 
osteoblasts stems from previous observations by Ominsky and colleagues who reported 
decreased number of lining cells and increased osteoblast number after Scl-Ab 
administration in rats (9). These findings are in line with previous studies showing that PTH 
administration to mice or rats, which markedly decreases Sost/Sclerostin expression (10;11), 
increased bone lining cell thickness and decreased their number while simultaneously 
increasing the number of osteoblasts on bone surfaces (12–14). In concert, these findings 
support the notion that suppression of sclerostin expression or function with PTH or the Scl-
Ab promotes lining cell reactivation into osteoblasts and provide a mechanism that may 
account for the rapid increases in osteoblast number and bone formation after treatment with 
either therapy. Further, these results infer that exhaustion of the pool of quiescent cells could 
underlie the declining efficacy of intermittent PTH or Scl-Ab therapies with time.
The assumed consequence of reactivation of bone lining cells with sclerostin inhibition is 
that the lining cell-derived osteoblasts would be responsible for increasing bone formation. 
However, one caveat of the study by Kim et at is that no evidence is presented showing that 
the “converted” osteoblasts indeed are able to form new bone, as bone formation in the areas 
covered by thicker lining cells was not reported. In addition, if indeed decreased sclerostin 
with daily injections of PTH mediates activation of lining cells, the contribution of this 
phenomenon to bone formation by the hormone appears to be minimal, as downregulation of 
sclerostin has been shown not to be required for the full anabolic effects of PTH (15;16). 
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Thus, future experiments using fluorochrome labeled bone are required to quantify by 
dynamic histomorphometry the contribution of lining cell activation to the bone anabolic 
effects of Scl-ab and/or PTH. Further, lining cell activation was not due to changes in the 
prevalence of apoptosis or proliferation; therefore, conversion into matrix producing cells 
might involve changes in cellular metabolism. In addition, it is not known whether 
stimulation of the biosynthetic capacity of the lining cells is also achieved by other activators 
of canonical Wnt/β catenin signaling. Future studies are warranted to clarify these 
unresolved issues.
One intriguing finding of the study of Kim et al is that, besides increasing the thickness of 
lining cells, Scl-Ab also augmented the total number of genetically labelled lining cells 
covering bone surfaces (5). This result contrasts with the increase in osteoblast number 
without changes in the total number of cells on bone surfaces upon PTH administration 
previously quantified by using a similar approach (12). One potential explanation for this 
apparent discordancy is that transient versus sustained decreases in sclerostin expression 
achieved by daily PTH injections or the Scl-Ab, respectively, could result in activation of 
some versus all lining cells, or in the recruitment of different cell populations by Scl-ab. 
Indeed, Kim et al found in the marrow OCN-tdTomato positive cells that could contribute to 
the increased numbers of genetically labeled cells on endocortical bone surfaces (5). The 
contribution of other cell populations besides lining cells is potentially important, as it is 
difficult to reconcile that the increased number of osteoblasts could be solely explained by 
conversion of lining cells considering that the bone surface covered by a lining cell is much 
greater (> 5 times) than the one covered by an osteoblast (17;18). Further studies combining 
different methodologies are needed to confirm these findings, and to investigate whether 
treatment with the Scl-Ab reactivates lining cells also on cancellous bone surfaces, which 
was not addressed in the current study.
Sclerostin contributes to beige adipogenesis in peripheral fat depots
The second study by Fulzele et al provides strong evidence for a role of osteocyte-derived 
sclerostin in a tissue other than bone. Specifically, the authors demonstrate that 3 different 
genetically modified mouse models with loss of the stimulatory subunit of G-proteins Gsα 
exhibit increased sclerostin in the circulation and a progressive loss of WAT in gonadal and 
inguinal stores. The reduced WAT mass was associated with decreased white adipocyte 
markers, increased beige adipocytes, and reduced canonical Wnt/catenin signaling in these 
fat depots (6). Beige adipocytes are brown-adipocyte-like cells present in WAT that express 
the uncoupling protein 1 (UCP1), a mitochondrial protein responsible for dissipating 
chemical energy to generate heat (19). Fulzele et al also show that conditioned media from a 
newly generated osteocytic cell line lacking Gsα and secreting high levels of sclerostin 
increase the expression of UCP1 by primary adipocytes, and this effect was partially 
reversed by depletion of sclerostin from the conditioned media. Furthermore, Gsα deficient 
mice treated with Scl-Ab exhibited reduced UCP1 expression in WAT; and, conversely, WT 
mice treated with mouse recombinant sclerostin displayed increased UCP1 expression in 
WAT. These findings of Fulzele, Divieti Pajevic, and collaborators demonstrate that bone-
derived sclerostin is involved in the genesis of beige adipocytes in peripheral fat depots and 
add to the increasing list of bone-derived factors with extra-skeletal effects, highlighting the 
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role of the skeleton as an endocrine organ with the capacity of regulating the function and 
metabolism of other tissues (20;21)
Sclerostin has been previously shown to positively regulate the differentiation of cells of the 
adipocyte lineage, as well as marrow adipocytes. An in vitro study showed that sclerostin 
increases the differentiation of preadipocytic 3T3-L1 cells, upregulating adipocyte genes and 
inducing lipid droplets accumulation (22). Moreover, radiation increases sclerostin 
expression and the number of bone marrow adipocytes, an effect that was reversed by Scl-
Ab or genetic deletion of Sost (23). These findings had suggested a potential role of 
sclerostin in fat metabolism, in particular in the bone/bone marrow microenvironment. 
However, the current study emphasizes the ability of sclerostin to negatively regulate 
adipogenesis in remote organs. Therefore, it highlights the potential biological role of 
circulating sclerostin and suggests that the mechanisms of sclerostin regulation of fat 
metabolism differ between bone marrow and peripheral fat depots. Consistent with the 
Fulzele et al study, Frey et al also showed that manipulation of Sost/sclersotin levels affect 
peripheral fat; however, they found opposite results, as overexproduction of sclerostin by 
adenoviral gene transfer increased fat pad weight, whereas Sost knockout mice exhibited 
decreased peripheral fat weight (24). Overall these findings warrant further investigation.
Fulzele et al propose that the mechanism by which high circulating sclerostin decreases 
body adiposity involves increased energy expenditure, as mice lacking GSα exhibit 
decreased food intake and physical activity in the face of normal or slightly elevated oxygen 
consumption. However, the effect on oxygen consumption is non-significant and no 
differences were found in the combined food intake, physical activity and oxygen 
consumption over a 24-h period compared to control mice. Thus, it is not clear whether 
these modest changes in energy expenditure could fully account for the striking decrease in 
WAT weight exhibited by the GSα knockout mice. Sclerostin administration to wild type 
mice also decreased WAT mass; however, it was not shown whether it increased energy 
expenditure. Nevertheless, these findings are provocative and justify future investigations to 
further explore the potential role of sclerostin as an endocrine regulator of energy and fat 
metabolism.
Conclusions
The two studies published in this JBMR issue (5;6) provide new insights into the functions 
of sclerostin in bone and compelling evidence that the protein also acts in non-skeletal 
tissues. The results reported by Kim, Wein and colleagues (5) suggest that suppression of 
sclerostin regulates bone formation at least in some quiescent surfaces by converting inactive 
lining cells into osteoblasts. These findings identify bone lining cells as cellular targets of 
Scl-Ab and suggest that this phenomenon could be used therapeutically to treat low bone 
mass conditions. The findings by Fulzele, Divieti Pajevic and colleagues (6) suggest that 
sclerostin, similar to other factors secreted by osteocytes/osteoblasts such as FGF-23 or 
osteocalcin, has an endocrine metabolic action complementary to its function in bone. 
Further investigations are needed to understand the relevance of circulating sclerostin levels 
and the effects of this protein in tissues other than bone.
Delgado-Calle and Bellido Page 4






















Grant support: This manuscript is supported by the National Institutes of Health (R01-AR059357, RO1-
AT008754, and AT008754-O2S1) and the Veterans Administration (I01 BX002104-01 ) to T.B.; and a Scholar 
Award from the American Society of Hematology and a Brian D. Novis Junior Research Grant from the 
International Myeloma Foundation to J.D.C.
Reference List
1. Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 
2017; 96:29–37. [PubMed: 27742498] 
2. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to 
treatments. Nat Med. 2013; 19(2):179–192. [PubMed: 23389618] 
3. Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of 
osteoporosis. Bone. 2017; 96:63–75. [PubMed: 27789417] 
4. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, ez-Perez A, et al. Romosozumab in 
Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. 2014; 370(5):412–420. 
[PubMed: 24382002] 
5. Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, et al. Sclerostin Antibody Administration 
Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res. 2016; doi: 10.1002/jbmr.
3038
6. Fulzele K, Lai F, Dedic C, Saini V, Uda Y, Shi C, et al. Osteocyte-Secreted Wnt Signaling Inhibitor 
Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots. J Bone Miner Res. 2017; 
32(2):373–384. [PubMed: 27653320] 
7. Miller SC, de Saint-Georges L, Bowman BM, Jee WS. Bone lining cells: structure and function. 
Scanning Microsc. 1989; 3(3):953–960. [PubMed: 2694361] 
8. Miller SC, Jee WS. The bone lining cell: a distinct phenotype? Calcif Tissue Int. 1987; 41(1):1–5.
9. Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, et al. Differential temporal 
effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and 
quantitative differences in effects on the osteoblast lineage in young intact rats. Bone. 2015; 
81:380–391. [PubMed: 26261096] 
10. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, et al. Chronic elevation of PTH in mice 
reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of 
osteoblastogenesis. Endocrinology. 2005; 146(11):4577–4583. [PubMed: 16081646] 
11. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37(2):148–158. 
[PubMed: 15946907] 
12. Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, et al. Intermittent PTH administration 
converts quiescent lining cells to active osteoblasts. J Bone Miner Res. 2012; 27(10):2075–2084. 
[PubMed: 22623172] 
13. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases 
bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136:3632–
3638. [PubMed: 7628403] 
14. Leaffer D, Sweeney M, Kellerman LA, Avnur Z, Krstenansky JL, Vickery BH, et al. Modulation of 
osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-
related peptide-(1–34), and bovine PTH-(1–34). Endocrinology. 1995; 136(8):3624–3631. 
[PubMed: 7628402] 
15. Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini G, et al. Control of 
bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream 
of the PTH receptor. J Bone Miner Res. 2016; doi: 10.1002/jbmr.3011
16. Robling AG, Kedlaya R, Ellis SN, Childress PJ, Bidwell JP, Bellido T, et al. Anabolic and catabolic 
regimens of human parathyroid hormone 1–34 elicit bone- and envelope-specific attenuation of 
skeletal effects in Sost-deficient mice. Endocrinology. 2011; 152(8):2963–2975. [PubMed: 
21652726] 
Delgado-Calle and Bellido Page 5





















17. Parfitt AM. The bone remodeling compartment: a circulatory function for bone lining cells. J Bone 
Miner Res. 2001; 16(9):1583–1585. [PubMed: 11547827] 
18. Miller, SC., Jee, WS. Bone lining cells. Hall, BK., editor. Bone. Boca Raton, FL, USA: CRC Press; 
1992. p. 1-19.
19. Kajimura S, Spiegelman BM, Seale P. Brown and Beige Fat: Physiological Roles beyond Heat 
Generation. Cell Metab. 2015; 22(4):546–559. [PubMed: 26445512] 
20. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr Rev. 
2013; 34(5):658–690. [PubMed: 23612223] 
21. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012; 
481(7381):314–320. [PubMed: 22258610] 
22. Ukita M, Yamaguchi T, Ohata N, Tamura M. Sclerostin Enhances Adipocyte Differentiation in 
3T3-L1 Cells. J Cell Biochem. 2016; 117(6):1419–1428. [PubMed: 26553151] 
23. Chandra A, Lin T, Young T, Tong W, Ma X, Tseng WJ, et al. Suppression of Sclerostin Alleviates 
Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through 
Distinct Mechanisms. J Bone Miner Res. 2017; 32(2):360–372. [PubMed: 27635523] 
24. Frey J, Kim S, Li Z, Tomlinson R, Hussain M, Thorek D, et al. Sclerostin influences body 
composition by regulating catabolic and anabolic metabolism in adipocytes. Journal of Bone and 
Mineral Research. 2016; 31(Supl 1):S12.
Delgado-Calle and Bellido Page 6
J Bone Miner Res. Author manuscript; available in PMC 2018 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
